Tyme Technologies Inc

Tyme Technologies — Investor Presentation (January 2019)

20 slides from Tyme Technologies's investor presentation, Jan 18, 2019

  1. Slide 1: January 2019 Investor Presentation

    January 2019 NASDAQ: TYME Exhibit 99.2

  2. Slide 2: Tyme is an emerging biotechnology company

    TYME IS AN EMERGING BIOTECHNOLOGY COMPANY COMMITTED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF INNOVATIVE METABOLIC-BASED THERAPIES ADVANCING MEDICAL INNOVATION THAT HELPS CANCER PATIENTS LIVE LONGER BETTER LIVES AND REDUCING THE BURDEN ON HEALTHCARE

  3. Slide 3: Safe Harbor Statement

    eal al Safe Harbor Statement Certain statements in this presentation and associated oral statements are “forward-looking statements” under the Private Securities Litigation Reform Act. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of r

  4. Slide 4: Overview

    Overview Steve Hoffman, Chairman & CEO Ben R. Taylor, President & CFO

  5. Slide 5: Benchmarking 3rd Line Pancreatic Cancer

    Benchmarking 3rd Line Pancreatic Cancer Michele Korfin, Chief Commercial Officer

  6. Slide 6: Pancreatic Treatment Paradigm

    > 10,000 Receive 3rd Line TYME-88-PANC Monotherapy > 20,000 Receive 2nd Line Onivyde® +5FU/LV (GA-failed) GA (5FU-failed) Single agent (ECOG 2) PP Monotherapy Arm PP GA-combo Arm TYME-88-PANC Monotherapy > 41,000 Receive 1st Line Gemzar® / Abraxane® (“GA”); or FOLFIRINOX Single agent (ECOG 2) Precis

  7. Slide 7: Historical Trial Outcomes in 2nd Line or Later Pancreatic Cancer

    Historical Trial Outcomes in 2nd Line or Later Pancreatic Cancer Expected median OS: ~6m in 2L and 3m after 2L progression Responses are rare, likely due to fibrotic tumor structure ~8% ORR in 2L and 0-2% in 3L Arm N ORR Median Months 2L PFS 2L OS OS post 2L PFS NAPOLI-1 Onivyde+5FU/LV 117 7.7% 3.1

  8. Slide 8: Historical Pancreatic Tumor Responses

    Historical Pancreatic Tumor Responses Existing therapies have shown OS benefit, but with few RECIST responses due to pancreatic tumor fibrosis Thick stromal fibrosis often remains even if there is treatment benefit An estimated ~10% of pancreatic tumors are cancer cells1 SM-88 will only target cance

  9. Slide 9: 88-Panc preliminary results

    88-Panc preliminary results Dr. Vincent Picozzi, Director of the Pancreas Center of Excellence at Virginia Mason Medical Center Dr. Giuseppe Del Priore, Chief Medical Officer

  10. Slide 10: 88-PANC Demographics

    88-PANC Demographics All subjects had actively progressing metastatic pancreatic cancer that had failed at least one prior line of chemotherapy Demographics Median / # Evaluable Per Protocol (Enrolled >1m) 28 (38 enrolled) Age 67 (46 – 86) Line of Therapy 3rd 2nd 14% (4) 3rd 50% (14) 4th + 36% (10)

  11. Slide 11: Safety Evaluation: 88-Panc Preliminary Data

    Safety Evaluation: 88-Panc Preliminary Data Favorable safety profile compared to chemotherapy Almost all patients report drug-related AEs under existing standard of care therapies Only 40% of patients have reported AEs possibly/related to SM-88 All possibly/related SAEs occurred in one patient Subje

  12. Slide 12: 88-PANC Overall Survival to Date

    88-PANC Overall Survival to Date (68% Alive at +4.3m Median Follow-up) Source: Data as of 1/6/19 from the Inform Electronic Data Capture system and/or related clinical systems. Overall Survival (months) Line of Therapy Subjects (n) Expected Median Current Follow-up % Alive 2nd 4 6.1m* +5.7m 0.75 3rd

  13. Slide 13: Case Study of Tumor Response

    Case Study of Tumor Response After 80 Days Baseline Multiple Liver Lesions Completely Resolved 4.87 cm x 4.22 cm 2.80 cm x 3.48 cm Large Pancreatic Tumor with Shrinkage of ~30%

  14. Slide 14: Imaging Analysis: 88-Panc Preliminary Data

    Imaging Analysis: 88-Panc Preliminary Data All subjects entered trial with confirmed actively progressing disease 47% (8/17) considered RECIST stable disease or better at two-months1 12% (2/17) of subjects showed target lesion partial response 2nd / 3rd Line subjects generally performed better 7/11

  15. Slide 15: Circulating Tumor Cell Responses: 88-Panc Preliminary Results

    Circulating Tumor Cell Responses: 88-Panc Preliminary Results 70% of subjects with >30% decline for at least one cycle Median 73% decrease Similar to response seen in Phase Ib/II prostate cancer trial Source: Data as of 1/6/19 from the Inform Electronic Data Capture system and/or Fluxion Biosystems.

  16. Slide 16: Next Steps in 3rd Line PC

    Next Steps in 3rd Line PC Summary of Enrollment Overlap Between Pancreatic Trials Precision Promise program provides an approval pathway for 1st & 2nd line pancreatic cancer through Discussing appropriate approval pathway with FDA in 3rd line setting Clear unmet need with no existing standard of car

  17. Slide 17: Conclusion

    Conclusion Ben Taylor, President & CFO Steve Hoffman, Chairman & CEO

  18. Slide 18: 2019 Planned Corporate Catalysts

    2019 Planned Corporate Catalysts 1Q:19Initiation of Phase II sarcoma trial 1H:19Initiation of Precision Promise Trial, 2nd-line monotherapy 1H:19Regulatory update of 3rd-line pancreatic pathway 1H:19Phase II pancreatic cancer trial, Stage 1 update 1H:19Preclinical data with SM-88 2H:19Initiate secon

  19. Slide 19: SM-88 Opportunity

    SM-88 Opportunity Proof-of-Concept in pancreatic and prostate could offer a path for SM-88 development into many of the 15 cancers where efficacy has been documented Proof of Concept Trials Cancers with Demonstrated Responses to SM-88 Pancreatic Breast Ovarian Prostate Colon Glioma/Glioblastoma Ewin

  20. Slide 20: Questions

    QUESTIONS TYMEO Cro

Tyme Technologies — Investor Presentation (January 2019) on 6ix